- Altimmune Inc OLD announced topline results from its 24-week (12-week extension) study of pemvidutide in patients with non-alcoholic fatty liver disease (NAFLD).
- Sixty-six of the 83 subjects who completed the initial 12-week Phase 1b NAFLD study consented to participate in this 12-week extension study to receive 24 weeks of treatment, and 64 subjects were enrolled.
- The study met its primary endpoint in all pemvidutide treatment groups.
- At the 1.8 mg and 2.4 mg doses, patients receiving pemvidutide achieved a mean relative reduction in liver fat content of 75.2% and 76.4%, respectively.
- 92.3% and 100% of the subjects achieved a 30% reduction in liver fat and 84.6% and 72.7% of the subjects achieved a 50% reduction in liver fat.
- 53.8% and 45.5% of the subjects achieved a normalization of liver fat.
- Significant reductions in serum alanine aminotransferase (ALT) and corrected T1 (cT1), both established markers of liver inflammation, were observed.
- Mean weight loss of 7.2% (placebo-adjusted 6.0%) in patients without diabetes at the 1.8 mg dose.
- The Company looks forward to the weight loss data from the interim analysis of the MOMENTUM obesity study in Q1 2023 and the initiation of a Phase 2b NASH study in 2023.
- Price promotion: ALT shares are up 10.20% to $11.31 on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
